158 related articles for article (PubMed ID: 35147134)
1. Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study.
Oi H; Matsuda T; Kimura T; Morise M; Yamano Y; Yokoyama T; Kataoka K; Kondoh Y
Medicine (Baltimore); 2022 Feb; 101(6):e28863. PubMed ID: 35147134
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer.
Matsui Y; Yamada T; Morimoto K; Katayama Y; Hiranuma O; Shiotsu S; Tamiya N; Takeda T; Morimoto Y; Iwasaku M; Tokuda S; Takayama K
Anticancer Res; 2022 Oct; 42(10):4921-4928. PubMed ID: 36191970
[TBL] [Abstract][Full Text] [Related]
3. Impact of nab-paclitaxel plus PD-1/PD-L1 inhibitor on chemorefractory relapsed small-cell lung cancer.
Mu F; Fan B; Li H; Qin W; Wang C; Zou B; Wang L
Future Oncol; 2023 Jun; 19(19):1367-1378. PubMed ID: 37114967
[TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel Monotherapy for Relapsed Small Cell Lung Cancer: Retrospective Analysis and Review.
Nakao M; Fujita K; Suzuki Y; Arakawa S; Sakai Y; Sato H; Muramatsu H
Anticancer Res; 2020 Mar; 40(3):1579-1585. PubMed ID: 32132060
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis.
Naito Y; Tamiya A; Tamiya M; Kimura Y; Hamaguchi M; Saijo N; Kanazu M; Tokura S; Shiroyama T; Morisita N; Omachi N; Suzuki H; Okamoto N; Okishio K; Hirashima T; Atagi S
Medicine (Baltimore); 2017 Sep; 96(35):e7884. PubMed ID: 28858103
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
[TBL] [Abstract][Full Text] [Related]
8. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S
Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
[TBL] [Abstract][Full Text] [Related]
11. Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.
Saxena A; Schneider BJ; Christos PJ; Audibert LF; Cagney JM; Scheff RJ
Med Oncol; 2016 Feb; 33(2):13. PubMed ID: 26749586
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
[TBL] [Abstract][Full Text] [Related]
13. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
[TBL] [Abstract][Full Text] [Related]
14. Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel.
Horiuchi M; Uemura T; Oguri T; Toda S; Yamamoto S; Suzuki Y; Kagawa Y; Sone K; Fukuda S; Mori Y; Fukumitsu K; Kanemitsu Y; Tajiri T; Ohkubo H; Takemura M; Ito Y; Maeno K; Niimi A
Invest New Drugs; 2022 Oct; 40(5):934-943. PubMed ID: 35759133
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.
Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T
J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Gelsomino F; Tiseo M; Barbieri F; Riccardi F; Cavanna L; Frassoldati A; Delmonte A; Longo L; Dazzi C; Cinieri S; Colantonio I; Sperandi F; Lamberti G; Brocchi S; Tofani L; Boni L; Ardizzoni A
Br J Cancer; 2020 Jul; 123(1):26-32. PubMed ID: 32346071
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience.
Wang Y; Li L; Xu C
Technol Cancer Res Treat; 2021; 20():15330338211050775. PubMed ID: 34657492
[No Abstract] [Full Text] [Related]
18. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer.
Kotake M; Kuwako T; Imai H; Tomizawa Y; Kaira K; Yoshii A; Ochiai M; Miura Y; Osaki T; Sakurai R; Takei K; Minato K; Saito R
Chemotherapy; 2020; 65(1-2):21-28. PubMed ID: 32674095
[TBL] [Abstract][Full Text] [Related]
20. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
Morgensztern D; Cobo M; Ponce Aix S; Postmus PE; Lewanski CR; Bennouna J; Fischer JR; Juan-Vidal O; Stewart DJ; Fasola G; Ardizzoni A; Bhore R; Wolfsteiner M; Talbot DC; Jin Ong T; Govindan R; On Behalf Of The Abound L Investigators
Cancer; 2018 Dec; 124(24):4667-4675. PubMed ID: 30383906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
